Guido Grassi
0000-0003-1922-6547
9 papers found
Refreshing results…
Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines
The role of β-blockers in medical treatment
Mechanisms of Vascular Inflammation and Potential Therapeutic Targets: A Position Paper From the ESH Working Group on Small Arteries
Rationale of treatment recommendations in the 2023 ESH hypertension guidelines
Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified
Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines
Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension
Association Between Atrial, Ventricular and Vascular Morphofunctional Alterations in Rheumatoid Arthritis
Sex-related relationships between uric acid and target organ damage in hypertension
Missing publications? Search for publications with a matching author name.